Objective: Ginsenosides play an important role in the treatment of diabetes and obesity. Our group predicted that ginsenoside Rb1 combined with insulin would have a protective effect in diabetic cardiomyopathy (DCM). Method: A diabetic model was induced in eight-week-old male Sprague-Dawley rats with a single intraperitoneal injection of 70 mg / kg streptozotocin. The rats were randomly divided into 4 groups (10 rats per group) and given different treatment for 6 weeks. During this period, all rats regularly took blood from the tail vein, regularly measured random blood glucose, and measured fasting weight regularly. After 6 weeks of intervention, all groups of rats underwent cardiac ultrasonography to evaluate cardiac function. Blood was taken from the aorta for biochemical testing, and heart tissue samples were taken for pathological staining, immunohistochemical staining, RT-PCR, Western blot, and ELISA detection. Result: Compared with the normal group, DCM rats displayed severe hyperglycemia, lower body weight, poorer cardiac performance, cardiac fibrosis and cardiac inflammation. DCM rats suffered obvious effects from over-activation of the EGF pathway. Ginsenoside Rb1 treatment attenuated hyperglycemia, body weight loss, and cardiac injury, as well as EGF activation induced by DCM. Meanwhile, ginsenoside Rb1 had no obvious toxicity or side effects in the heart, liver, or kidneys. Conclusion: Ginsenoside Rb1 treatment in diabetic rats can inhibit the over-activated EGF signaling pathway, attenuate fibrosis of myocardial tissue, and improve cardiac function, and has no obvious toxicity or side effects. It is a potential drug for diabetic heart disease.